Takeda claims Aurora A kinase inhibitor lead as it takes alisertib into Phase III
This article was originally published in Scrip
Executive Summary
Takeda and its oncology arm Millennium have initiated what they claim is the first Phase III trial worldwide with a novel class of oral small molecule kinase inhibitor.